Medicines, radiological examinations and physiotherapy: the new healthcare expenses that will impact your budget

As economic and social challenges intensify, health-related expenses continue to rise, placing increasing pressure on household budgets and public finances. By 2025, a significant turning point is emerging around three major areas: innovative medicines, radiological examinations, and physiotherapy sessions. These sectors, long supported by generous reimbursements, are now seeing their direct costs increase for insured individuals, notably due to government adjustments aimed at replenishing Social Security funds. This development highlights complex issues that intertwine medical innovation, expenditure control, and equitable access to care. Pharmaceutical industries such as Sanofi, Pfizer, or Novartis, as well as medical diagnostics players like Siemens Healthineers and GE Healthcare, play a central role in this dynamic. In this context, new medical deductibles and direct payment methods at pharmacies are permanently transforming the relationship between patients, healthcare professionals, and health insurance.

Faced with these changes, consumers and sector professionals alike must navigate between major therapeutic advances and increased financial constraints. The impressive progress made in pharmaceuticals, widely reported by studies and initiatives from Roche, Eli Lilly, or Boehringer Ingelheim, cannot hide the substantial economic impact that results. Radiology and physiotherapy, essential for diagnosis and follow-up, are also at a crossroads where technological innovation goes hand in hand with rising costs. What are the precise implications of these transformations? How do current measures affect personal budgets? And what strategies are emerging to reconcile healthcare excellence with financial sustainability? This article offers a detailed analysis, supported by recent data, to understand the new landscape of health spending in 2025.

Innovative medicines: continuous expenditure growth driven by technologies and strengthened deductibles

The pharmaceutical sector is experiencing unprecedented upheaval caused by the massive arrival of innovative drugs. These new treatments, developed notably by laboratories such as Sanofi, Pfizer, and Novartis, often incorporate cutting-edge technologies like gene therapy, monoclonal antibodies, or targeted biotherapies. While these advances hold hope for previously incurable diseases, they significantly impact overall care costs. The Court of Auditors, in its recent detailed recommendations, points to a price inflation that could threaten the balance of public health expenditures by 2030.

It is noteworthy that medical deductibles have been significantly increased since 2024: the annual cap has risen from 100 euros to 200 euros, imposing a higher remaining charge on patients. These deductibles directly concern medicines and are now paid directly at the pharmacy, without subsequent deduction by Social Security or supplementary health insurance. This policy, intended to “make insured individuals more responsible,” according to Minister Catherine Vautrin, has sparked considerable debate. Patients with long-term illnesses, even if partially exempted, must now cope with substantial additional expenses.

• 💊 The arrival of costly treatments from Eli Lilly and Boehringer Ingelheim increases medication expenses.
• 🛡️ Strengthened deductibles impose direct payments, especially affecting chronic conditions.
• 📉 These measures aim to generate 700 million euros in savings by 2026 but exacerbate insured individuals’ financial difficulties.
• 🔬 Research and development continue to expand the therapeutic portfolio, increasing funding needs.

Element	Situation before May 2024	Situation from May 2024	Projection 2025
Annual deductible cap	100 €	100 € (no change)	200 €
Deductible per medication box	0.50 €	1 €	2 € envisaged
Participation flat-rate consultations	1 €	2 €	Possible increase
Exempted patients	Minors, pregnant women, CMU beneficiaries	Same	Gradual removal of exemptions

Industries like Bayer or Roche must also adapt to this context where greater transparency on prices is required. Highlighting these developments shows that, while pharmaceutical innovations represent a major advance in health, they also necessitate a determined effort to control long-term costs.

Radiological examinations: a cost explosion at the crossroads of technology and deductibles

The increased use of medical imaging techniques constitutes another expense category experiencing rapid growth. The arrival of more advanced machines, such as those offered by Thermo Fisher Scientific, GE Healthcare, or Siemens Healthineers, allows for more precise and faster diagnoses. However, this technical sophistication comes at a price: the acquisition, maintenance, and servicing of these devices represent significant investments for healthcare facilities. Consequently, the cost of radiological exams is trending upward, further pressuring social security budgets and insured individuals’ finances.

A key issue raised by radiologists in various forums is increasing outrage over rising medical deductibles affecting these procedures. Now, patients are required to pay directly at the pharmacy or during the exam, amounts that can reach 8 euros per day. This cap, doubled since 2024, along with the increase in the annual ceiling, weighs heavily on household budgets, especially for those requiring frequent care.

• 🩻 New radiological technology improves early detection of pathologies.
• 💸 Rising costs: equipment and operation require increased funding.
• 😠 Mixed reactions from professionals regarding stricter deductibles.
• 📊 A spending distribution that must consider patients’ real needs.

Type of exam	Average cost (€)	Daily deductible (€)	Annual ceiling (€)
Simple X-ray	25	8	200
Scanner	110	8	200
MRI	140	8	200
Ultrasound	60	8	200

In this context, insured individuals must now incorporate higher indirect health costs into their budgets. It is also important to note that official recommendations encourage a rational use of radiological exams to limit unnecessary expenses while ensuring care quality.

Physiotherapy: increasing sessions and costs, a daily financial impact

Physiotherapy, in turn, represents a health expense category expected to grow. This discipline covers a wide range of pathologies, from post-operative rehabilitation to chronic pain. Demand has increased due to the aging population, and treatments often last long and are repetitive. The gradual inclusion of new techniques and high-end equipment by some practitioners also adds to the bill.

The government has, in parallel, reinforced flat-rate deductibles in this sector as part of broader Social Security cost-saving measures. This development results in a significant remaining charge for patients, who must now anticipate higher financial participation without possible reimbursement from their supplementary insurers. This trend highlights the vulnerability of users, especially those with long-term conditions.

• 🦾 Growing demand for physiotherapy sessions linked to population aging.
• 💰 Increase in the remaining charge due to high deductibles and direct payments.
• 🏥 Technical innovation in the sector, with the integration of connected or robotic devices.
• ⚠️ Risk of care limitations for the most vulnerable patients.

Type of session	Average cost (€)	Daily deductible (€)	Annual ceiling (€)
Classical physiotherapy	16	8	200
Specialized physiotherapy	25	8	200
Connected device session	40	8	200

The combined effect of direct and indirect costs in this field poses a major public health challenge. Restrictive measures could therefore create real barriers to care access for certain patients, increasing inequalities.

Government measures for control and their impact on insured individuals

The government has taken a decisive turn to control healthcare spending, implementing policies such as increasing medical deductibles and requiring direct payment at pharmacies. These measures, gradually introduced since 2024, aim to generate over 700 million euros in savings by 2026. This strategy relies on a triptych:

1. 📈 Increase in deductibles per act (consultations, medicines, exams, transport, physiotherapy).
2. 💳 Obligation of direct payment by the patient, reducing reimbursement complexity.
3. 🛡️ Restriction of exemption numbers, starting with progressive limits for long-term illnesses.

It should be noted that some profiles remain temporarily exempt, notably minors, pregnant women, and beneficiaries of supplementary health coverage. However, the tightening of rules encourages a change in attitude, where patients are called to better evaluate their needs and moderate their healthcare use.

• 🔍 Better insured responsibility within the system.
• ⚖️ Increased risk of forgoing care among vulnerable populations.
• 📊 Need for rigorous monitoring of healthcare expenses by authorities.
• 📅 Future prospects based on economic results.

The 2025 Revenue and Expenditure Report, published by Health Insurance, affirms a desire for a swift recovery without compromising care quality but also emphasizes the danger of “breaking out of the illusion of everything being free” to reach these goals. These measures are already in place but warrant particular vigilance regarding their implementation and future adjustments.

Main players in the pharmaceutical and medical industry facing economic challenges

Pharmaceutical laboratories like Sanofi, Pfizer, Roche, Boehringer Ingelheim, Eli Lilly, Novartis, or Bayer play a central role in developing therapeutic solutions. Their ability to innovate directly influences health costs and public expenditure dynamics. The constant need to invest in research demands high prices, justified by complex technologies. This presents a paradox: patients benefit from the latest advances but must bear increasing costs.

Similarly, companies specializing in medical imaging such as Thermo Fisher Scientific, GE Healthcare, and Siemens Healthineers contribute to improved diagnostics, essential for optimal care. However, they also face budget fluctuations in healthcare facilities, which can limit rapid equipment renewal and affect exam quality.

• 💡 Technological innovation as a primary driver of expenses.
• 📉 Pressure on margins of companies and reimbursement systems.
• ⚙️ Need for increased collaboration between industry players and health authorities.
• 📚 Importance of price transparency and patient information.

Controlling costs while maintaining innovation is a major strategic challenge, creating tensions among stakeholders. This issue is discussed in publications from Medisite and in specialized reports available on Le Courrier des Échos.

Budgetary consequences for households and adaptation strategies

The rise in deductibles and the multiplication of direct expenses expose households to an increased risk of exceeding their health budget. According to data from DREES, the average annual remaining charge could reach 200 euros, double that of previous years. This reality is particularly concerning for low-income households and individuals with conditions requiring regular monitoring.

In response to this, several adaptation strategies are emerging:

• 💳 Subscribing to more comprehensive supplementary insurance, often at higher cost.
• 📅 Careful planning and organization of treatments to optimize expenses.
• 🔎 Actively seeking information about less costly therapeutic alternatives.
• 🤝 Increasing use of social and community services for financial support.

These behaviors reflect a collective awareness of the actual costs of care but can also lead to care abandonment, with serious health consequences. In-depth analyses available at Aide BTS Assurance highlight these risks.

Technological innovations to watch in the context of health expenses

Medicine and health technologies are rapidly evolving, with increasingly sophisticated equipment from recognized laboratories and companies like Thermo Fisher Scientific and Siemens Healthineers. These innovations affect medicines, medical devices, telemedicine, or diagnostic systems.

Despite their potential to improve care quality and early diagnosis, these advances often require heavy investments, both for healthcare facilities and households that face increased deductibles. The challenge is to support these changes while optimizing costs, as recommended by MedTech France.

• ⚙️ Development of telehealth and remote consultations, reducing certain costs.
• 🧬 Advances in personalized medicine through genetic analysis.
• 📡 Integration of connected devices to monitor chronic patients.
• 🔄 Automation and robotics in rehabilitation and surgery.

These trends explain part of the increase in expenses but also offer opportunities for better resource management and more effective care, as discussed in reports from MedTech France.

Critical voices and future perspectives for controlling healthcare expenses

In the face of growing economic pressure, several voices are raising concerns about potential abuses related to increasing deductibles and the transfer of costs to insured individuals. Field actors, notably radiologists and healthcare professionals, express increasing anxiety about access to care for the most vulnerable. The risk of abandonment of care, especially among patients with chronic illnesses, is at the heart of debates.

The government, while supporting these measures, calls for greater responsibility from insured individuals and moderation in consumption. However, some experts advocate for a broader reflection on healthcare financing, aiming to restore a balance between innovation, quality, and sustainability.

• 📢 Calls for revising deductibles to preserve access to care.
• ⚠️ Warning against increasing health inequalities.
• 💼 Necessity for public investments in prevention and health education.
• 📈 Search for alternative supplementary financing for Social Security.

These issues are widely debated in political and economic circles, as reflected in analyses presented on Aide BTS Assurance or in official reports. The future of the healthcare system remains a major challenge, where every decision directly impacts household budgets and care quality.

FAQ on the impact of new healthcare expense items in 2025

• Q: Why have medical deductibles been increased?
  A: The government seeks to reduce Social Security deficits by increasing deductibles, thereby encouraging patients to moderate their care consumption and generate 700 million euros in savings by 2026.
• Q: Which patients are still exempt from deductibles?
  A: Minors, pregnant women, and beneficiaries of complementary health coverage remain exempt, but several exemptions may be reviewed soon.
• Q: How does this increase affect household budgets?
  A: It can raise the annual remaining charge to 200 euros, particularly impacting those requiring regular care and low-income families.
• Q: Are there less costly alternatives to innovative medicines?
  A: Some generics and biosimilars offer alternatives, but their availability varies by pathology. Patients should consult their doctor.
• Q: Can new medical technologies reduce healthcare expenses?
  A: They can optimize diagnostics and treatments but often require high initial investments, which may lead to increased costs in the short term.

Source: www.capital.fr